Richard Gilbert - Targeting fibrosis in Heart Failure: Fibrotech and Fibrocor

This presentation, presented on Friday, December 10th, 2021 was part of the sixth annual 2021 Ted Rogers Centre Heart Failure Symposium.
The sixth annual Ted Rogers Centre Heart Failure Symposium was held virtually from December 10-11, 2021. This meeting, which blends clinical innovations with the latest scientific advances, has grown to become Canada’s largest conference on heart failure.
On Friday, December 10th, our research-focused symposium examines congenital heart disease, and how we can take animal models and regenerative medicine approaches to answer the clinical challenges that remain. It also highlights commercialization success stories, and sees how innovators developed an idea and translated it to impact. And it will shine a light on unique new scientific approaches in the emerging field of cardiotoxicity.
About the speaker:
Richard Gilbert (MD, PhD, FRCPC) is professor of medicine at the University of Toronto, Canada Research Chair in Diabetes Complications, and head of the division of endocrinology at St. Michael’s Hospital in Toronto. He co-founded Fibrotech, a biotech company that has brought novel anti-fibrotic therapies from the bench to early phase human trials. He then founded another biotech company, Fibrocor Therapeutics, for which he serves as chief scientific officer.
Learn more about the Centre:
tedrogersresea...
Keep in touch with us:
Twitter: @trogersresearch
LinkedIn: bit.ly/3wt6le3